Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Smith

Allergy & Immunology Sandy, UT Medical Doctor

NPI 1164468955 CMS profile 279295

7390 S Creek Rd Ste 201, Sandy, UT 84093

Open in the dashboard

General payments

$648,839

1,548 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$678,484 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Andrew Smith of Sandy, UT is reported in the CMS Open Payments database as having received $648,839 across 1,548 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $678,484 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $146,098 323
2024 General $151,883 284
2023 General $60,030 190
2022 General $114,365 262
2021 General $80,479 202
2020 General $28,694 109
2019 General $67,290 178

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Smith
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Andrew Smith were reported at $146,098. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Andrew Smith Allergy & Immunology median Middle half National median
2019 $67,290 $594 $163–$1,512 $163
2020 $28,694 $426 $106–$1,233 $114
2021 $80,479 $638 $157–$1,708 $132
2022 $114,365 $790 $205–$1,961 $149
2023 $60,030 $852 $220–$2,147 $160
2024 $151,883 $865 $203–$2,267 $164
2025 $146,098 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $219,931 416 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $145,637 215 payments
  3. Pharming Healthcare, Inc. $77,683 132 payments
  4. BioCryst US Sales Co., LLC $69,609 103 payments
  5. OptiNose US, Inc. $39,227 89 payments
  6. Shire North American Group Inc $27,450 39 payments
  7. CSL Behring $15,206 75 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $14,468 25 payments
  9. Amgen Inc. $6,262 24 payments
  10. Genzyme Corporation $4,863 81 payments
  11. Other $28,504 349 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $421,408 203 payments
  2. Consulting Fee $118,034 51 payments
  3. Travel and Lodging $62,390 275 payments
  4. Food and Beverage $29,951 1,007 payments
  5. Honoraria $16,851 6 payments
  6. Education $205 6 payments
Products named General payments · program years 2019–2025
  1. AIRSUPRA $124,241 165 payments
  2. CINRYZE $114,784 119 payments
  3. RUCONEST $77,683 132 payments
  4. Orladeyo $61,892 103 payments
  5. TAKHZYRO $45,815 70 payments
  6. TEZSPIRE $45,227 66 payments
  7. Xhance $39,227 89 payments
  8. FASENRA Respiratory $29,202 90 payments
  9. Haegarda $8,664 35 payments
  10. FASENRA Respiratory $6,669 28 payments
  11. Other $39,441 614 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,562

Median for Allergy/ Immunology: 449

Drug cost

$523,381

Median for Allergy/ Immunology: $169,700

Branded share of claims

34.3%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Icatibant Icatibant Acetate Brand 11 $115,515
Xolair Omalizumab Brand 26 $70,151
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 84 $69,297
Tezspire Tezepelumab-Ekko Brand 13 $55,875
Dupixent Pen Dupilumab Brand 13 $44,987
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 44 $34,074
Cromolyn Sodium Generic 39 $22,167
Spiriva Respimat Tiotropium Bromide Brand 29 $17,396
Dulera Mometasone/Formoterol Brand 17 $11,814
Breo Ellipta Fluticasone/Vilanterol Brand 17 $10,838

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$488,352

Of which drugs: $358,280

Medicare patients

282

Average age 72

Services billed

27,456

195 women, 87 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 55%
Arthritis 50%
Depression 28%
Diabetes 22%
Chronic kidney disease 20%
Osteoporosis 20%
Ischemic heart disease 16%
COPD 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 12 7,050 $185,024

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$54,043 — —
TAKHZYRO
$28,864 — —
RUCONEST
$18,389 — —
Xhance
$12,276 — —
TEZSPIRE
$4,423 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

1,548 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record